NCT05329857View on ClinicalTrials.gov

The Study Intends to Show Bioequivalence of the Test Product and the Reference Reference Product in a Crossover Design Study Healthy Volunteers. Additionally, the Safety Profile of Test Product Compared to Reference Product Will be Evaluated.

NACompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

January 31, 2016

Study Completion Date

March 31, 2016

Conditions
To Determine Bioequivalence Under Fed Conditions
Interventions
DRUG

Metformin and Vildagliptin 1000/50 mg

50 mg Vildagliptin + 1000 mg Metformin as single-dose per study period

All Listed Sponsors
lead

AET Laboratories Private Limited

INDUSTRY

NCT05329857 - The Study Intends to Show Bioequivalence of the Test Product and the Reference Reference Product in a Crossover Design Study Healthy Volunteers. Additionally, the Safety Profile of Test Product Compared to Reference Product Will be Evaluated. | Biotech Hunter | Biotech Hunter